# Karyopharm Therapeutics Inc. (KPTI)

> Source: Nexqual · https://nexqual.com/KPTI · data as of 2026-10-29 15:12 UTC · cite as "Nexqual, Karyopharm Therapeutics Inc. (KPTI), nexqual.com/KPTI" · informational, not investment advice.

**Price:** USD 0.86 (+3.34% today) · US market open, as of October 29, 2026 at 15:12 UTC; quotes may be delayed. Prev close 0.83 · day 0.79–0.99 · 52w 0.31–10.99 · market cap $19.5M · NMS

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $147M, net income -$225M (-153.3% margin) (SEC filings).
- Insider open-market sales, last ~7 months: 11 Form 4 filings, $42K; 11 not under a Rule 10b5-1 plan ($42K); 0 by opportunistic insiders, 7 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 1.80 on a 1–5 scale) (5 analysts), mean target USD 7.25 (range 3–11).
- Total return with dividends: 1Y -85.9% vs S&P 500 +13.2%; 5Y -99.0% vs S&P 500 +79.2%.
- Next earnings: 2026-11-03, EPS estimate USD -1.32, revenue estimate $33.5M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $210M | $157M | $146M | $145M | $146M | $147M |
| Operating income | -$98.3M | -$142M | -$130M | -$119M | -$90.7M | -$82.3M |
| Net income | -$124M | -$165M | -$143M | -$76.4M | -$196M | -$225M |
| EPS (diluted) | -$24.75 | -$30.30 | -$18.79 | -$14.00 | -$17.93 | — |
| Free cash flow | -$107M | -$150M | -$92.7M | -$128M | -$75.4M | — |
| Operating margin | -46.8% | -90.5% | -88.7% | -82.2% | -62.1% | -56.2% |
| Net margin | -59.1% | -105.2% | -98.0% | -52.6% | -134.2% | -153.3% |
| Revenue growth | +94.1% | -25.1% | -7.0% | -0.5% | +0.6% | — |
| Cash + short-term investments | $229M | $278M | $191M | $109M | $63.7M | — |
| Total debt | $169M | $170M | $171M | $0K | — | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/S 0.1x · Earnings yield -1152.29%

## Insider sales (SEC Form 4, open-market, last ~7 months)
0 of 11 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-10-16 | Abate Kristin | Chief Accounting Officer | 4,788 | $2K | 20.5% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-10-01 | Abate Kristin | Chief Accounting Officer | 378 | $0K | 1.6% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-09-01 | Abate Kristin | Chief Accounting Officer | 19 | $0K | 0.1% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-07-28 | Poulton Stuart | EVP, Chief Development Officer | 189 | $1K | 0.2% | No | Routine (sold in Feb & Jul each year 2023–2025) |
| 2026-05-14 | Poulton Stuart | EVP, Chief Development Officer | 403 | $4K | 0.4% | No | Routine (sold in Feb & Jul each year 2023–2025; this trade is outside those months) |
| 2026-05-14 | Rangwala Reshma | EVP & Chief Medical Officer | 408 | $4K | 0.7% | No | Routine (sold in Apr each year 2023–2025; this trade is outside those months) |
| 2026-05-14 | Cheng Sohanya Roshan | EVP & Chief Commercial Officer | 324 | $3K | 0.3% | No | Routine (sold in Mar & Sep each year 2023–2025; this trade is outside those months) |
| 2026-05-14 | Abate Kristin | Chief Accounting Officer | 53 | $1K | 0.2% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-05-14 | Paulson Richard A. | President and CEO | 2,203 | $21K | 0.8% | No | Routine (sold in Jan & Feb & Mar & Apr & May & Sep each year 2023–2025) |
| 2026-05-14 | Mano Michael | EVP, CLO&Secretary | 266 | $3K | 0.3% | No | Routine (sold in Mar & Sep each year 2023–2025; this trade is outside those months) |
| 2026-04-21 | Rangwala Reshma | EVP & Chief Medical Officer | 449 | $4K | 0.8% | No | Routine (sold in Apr each year 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus Buy (mean 1.80 on a 1–5 scale), 5 analysts; mean target USD 7.25 (low 3, high 11).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-31 | Piper Sandler | Target lowered | Overweight | $16 → $7 |
| 2026-07-31 | HC Wainwright & Co. | Downgrade | Buy → Neutral | $13 → $3 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-29) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | -85.9% | -99.0% |
| S&P 500 (SPY) | +13.2% | +79.2% |
| Per year | -85.9% | -59.7% |
| Volatility (annualized) | 178.4% | 117.7% |
| Max drawdown | -97.0% (Jul 2026→Oct 2026) | -99.8% (Feb 2022→Oct 2026) |

## Peers (Biotechnology)
ORKA (Oruka Therapeutics, Inc.) USD 97.35 +1.44% · LGND (Ligand Pharmaceuticals Incorpor) USD 315.88 -0.91% · IOVA (Iovance Biotherapeutics, Inc.) USD 9.6 -35.21% · IONS (Ionis Pharmaceuticals, Inc.) USD 45.31 +0.91% · AXSM (Axsome Therapeutics, Inc.) USD 143.35 -0.11% · ABVX (Abivax SA) USD 91.13 +1.44%

## More
Full page: https://nexqual.com/KPTI · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in KPTI's own 10-K filed 2026-02-13 (https://www.sec.gov/Archives/edgar/data/1503802/000119312526049397/kpti-20251231.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Customer | Antengene Therapeutics | "In May 2020, we entered into an amendment of our May 2018 license agreement with Antengene Therapeutics Limited ("Antengene") (the "Original Antengene Agreement", and, as amended, the "Amended Antengene Agreement")." |
| Partner | Promedico | "In February 2020, we entered into an exclusive distribution agreement with Promedico Ltd. ("Promedico") for the commercialization of XPOVIO in Israel, the West Bank, Gaza Strip and the territories under control of the Pa…" |
| Partner | Foundation Medicine | "Further, in connection with the XPORT-EC-042 Trial, we entered into a global collaboration with Foundation Medicine, Inc. to develop FoundationOne®CDx, a tissue-based next generation sequencing test to identify and enrol…" |
| Partner | Libo Pharma | "In July 2021, we entered into a license agreement with Libo Pharma Corp. ("Libo") under which we granted to Libo an exclusive license to manufacture, develop and commercialize Interleukin 12 products in certain countries…" |
| Partner | Jefferies | "In addition, we expect to evaluate opportunities to raise additional funds from time to time, including through the issuance and sale of shares of our common stock under our Open Market Sale Agreement with Jefferies LLC …" |
| Partner | FORUS Therapeutics | "For example, we are party to license arrangements with Antengene and Menarini and distribution agreements with Promedico Ltd. and FORUS Therapeutics Inc. for the development, marketing and/or commercialization of selinex…" |
| Partner | HealthCare Royalty Management | "In May 2024, we entered into an amendment (the "HCRx Amendment") to the Amended Revenue Interest Agreement with HCRx, pursuant to which we:" |

## Company outlook (8-K filed 2026-08-13)

- "Guidance of $130 Million to $150 Million Including U.S."
- "XPOVIO Net Product Revenue Guidance of $115 Million to $130 Million – – Conference Call Scheduled for Today at 8:00 a.m."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-1.31 | $-1.21 | −$0.10 | $33.5M | 2 |
| Next quarter (ends 2026-12-31) | $-1.21 | $-1.23 | +$0.02 | $34.3M | 2 |
| Current fiscal year (ends 2026-12-31) | $-5.84 | $-4.95 | −$0.89 | $135.6M | 2 |
| Next fiscal year (ends 2027-12-31) | $-2.82 | $-4.89 | +$2.07 | $173.6M | 2 |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$2.32 | −$1.39 | Miss −66.9% | — |
| — | Quarter ended Mar 31, 2026 | −$1.24 | −$1.44 | Beat +13.9% | — |
| — | Quarter ended Dec 31, 2025 | −$2.23 | −$2.00 | Miss −11.5% | — |
| — | Quarter ended Sep 30, 2025 | −$3.82 | −$3.25 | Miss −17.5% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

## Recent SEC filings (last 120 days)
| Filed | Form | What it says | Filing |
|---|---|---|---|
| 2026-10-28 | Schedule 13G/A | Integrated Core Strategies (US) LLC, Millennium Management LLC: 0.2% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1503802/000110465926119710/0001104659-26-119710-index.htm |
| 2026-10-22 | 8-K | Other material event — “As previously disclosed in the Current Reports on Form 8-K filed by Karyopharm Therapeutics Inc. (the "Company") on September 11, 2026 and October 14, 2026, the Company entered into a Forbearance Agreement and Limited Waiver to Indentures, dated September 10, 2026 (the "Forbearance Agreement"), and the applicable parties subsequently extended the Forbearance Period (as defined in the Forbearance Agreement) to October 22, 2026. On October 22, 2026, in accordance with Section 19 of the Forbearance Agreement, the…” | https://www.sec.gov/Archives/edgar/data/1503802/000119312526428938/0001193125-26-428938-index.htm |
| 2026-10-14 | 8-K | Other material event | https://www.sec.gov/Archives/edgar/data/1503802/000119312526421025/0001193125-26-421025-index.htm |
| 2026-10-08 | Schedule 13G/A | ACORN BIOVENTURES, L.P., ACORN CAPITAL ADVISORS GP, LLC: 4.5% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1503802/000163658726000086/0001636587-26-000086-index.htm |
| 2026-09-25 | Schedule 13G/A | ACORN BIOVENTURES, L.P., ACORN CAPITAL ADVISORS GP, LLC: 5.7% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1503802/000163658726000084/0001636587-26-000084-index.htm |
| 2026-09-25 | Schedule 13G/A | ACORN BIOVENTURES, L.P., ACORN CAPITAL ADVISORS GP, LLC: 5.7% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1503802/000163658726000083/0001636587-26-000083-index.htm |
| 2026-09-18 | 8-K | Change to shareholder rights; Bylaws or fiscal-year change | https://www.sec.gov/Archives/edgar/data/1503802/000119312526395517/0001193125-26-395517-index.htm |
| 2026-09-11 | 8-K | Entered a material agreement; Debt acceleration triggered; Unregistered sale of shares; Other material event — “Forbearance Agreement On September 10, 2026, Karyopharm Therapeutics Inc. (the "Company") and its subsidiary guarantors entered into a Forbearance Agreement and Limited Waiver to Indentures (the "Forbearance Agreement") to provide the Company with additional time to continue to advance its myelofibrosis program, further negotiate with its lenders, pursue strategic alternatives, or consummate an equity capital raise. The Forbearance Agreement is with (i) the lenders under the Company's Credit and Guaranty…” | https://www.sec.gov/Archives/edgar/data/1503802/000119312526388621/0001193125-26-388621-index.htm |
| 2026-09-04 | Schedule 13G | Integrated Core Strategies (US) LLC, Millennium Management LLC: 5.7% of shares, passive 5%+ holder | https://www.sec.gov/Archives/edgar/data/1503802/000110465926105556/0001104659-26-105556-index.htm |
| 2026-08-31 | 8-K | Other material event | https://www.sec.gov/Archives/edgar/data/1503802/000119312526375495/0001193125-26-375495-index.htm |
| 2026-08-14 | Schedule 13G/A | passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1503802/000123191926000925/0001231919-26-000925-index.htm |
| 2026-08-14 | Schedule 13G/A | passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1503802/000183194226000037/0001831942-26-000037-index.htm |
| 2026-08-13 | 10-Q | Quarterly report · period ended Jun 30, 2026 | https://www.sec.gov/Archives/edgar/data/1503802/000119312526347906/0001193125-26-347906-index.htm |
| 2026-08-13 | 8-K | Quarterly results | https://www.sec.gov/Archives/edgar/data/1503802/000119312526347897/0001193125-26-347897-index.htm |
Source: SEC EDGAR. Quotes are the opening words of each item as filed.